A drug developed by GlaxoSmithKline (GSK) – Get GlaxoSmithKline Plc Report and Vir Biotechnology (VIR) – Get Vir Biotechnology, Inc. Report that appears to be effective against the Omicron Covid variant has been approved by U.K. regulators.
Dan Janney is Alta Partners’ managing partner and joined the firm at its founding in 1996. He has over 30 years of early-stage life sciences investing experience and has helped fund and develop over 50 companies.
Larry joined Alta Partners as Controller in 2007 and was promoted to CFO in September 2013. As Alta’s CFO, Larry’s areas of responsibility include accounting, tax, financial reporting, cash and securities management, legal and human resources, and other administrative functions at the firm.
Dr. Peter Hudson is a physician and entrepreneur with over 25 years of experience founding, growing, and investing in healthcare technology, services, and digital health. Pete focuses on improving delivery efficiency through new models and technology.